These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Lieberman LA; Zeng W; Singh C; Wang W; Otipoby KL; Loh C; Plavina T; Gorelik L; Ransohoff RM; Cahir-McFarland E Neurology; 2016 Jan; 86(4):375-81. PubMed ID: 26718566 [TBL] [Abstract][Full Text] [Related]
4. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. Spadaro M; Caldano M; Marnetto F; Lugaresi A; Bertolotto A J Neuroinflammation; 2015 Aug; 12():146. PubMed ID: 26259673 [TBL] [Abstract][Full Text] [Related]
5. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients. Jilek S; Mathias A; Canales M; Lysandropoulos A; Pantaleo G; Schluep M; Du Pasquier RA Mult Scler; 2014 Jun; 20(7):837-42. PubMed ID: 24258149 [TBL] [Abstract][Full Text] [Related]
6. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases. N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928 [TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Fissolo N; Pignolet B; Matute-Blanch C; Triviño JC; Miró B; Mota M; Perez-Hoyos S; Sanchez A; Vermersch P; Ruet A; de Sèze J; Labauge P; Vukusic S; Papeix C; Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Montalban X; Brassat D; Comabella M; Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388 [TBL] [Abstract][Full Text] [Related]
8. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957 [TBL] [Abstract][Full Text] [Related]
9. PML risk stratification using anti-JCV antibody index and L-selectin. Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858 [TBL] [Abstract][Full Text] [Related]
10. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients. Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768 [TBL] [Abstract][Full Text] [Related]
18. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921 [TBL] [Abstract][Full Text] [Related]
19. Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient. Sottini A; Capra R; Zanotti C; Chiarini M; Serana F; Ricotta D; Caimi L; Imberti L PLoS One; 2012; 7(4):e34493. PubMed ID: 22496817 [TBL] [Abstract][Full Text] [Related]
20. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]